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Abstract: Gold compounds have been proven to be novel and versatile tools for biological applications,
including as anticancer agents. Recently, we explored the potential of Au(III) complexes with
bi-dentate N-donor ligands as inhibitors of the membrane water and glycerol channels aquaporins
(AQPs), involved in different physiological and pathophysiological pathways. Here, eight new Au(III)
complexes featuring a pyridine-benzimidazole scaffold have been synthesized and characterized via
different methods. The stability of all the compounds in aqueous solution and their reactivity with
glutathione have been investigated by UV–visible spectroscopy. The Au(III) compounds, tested for
their AQPs inhibition properties in human Red Blood Cells (hRBC), are potent and selective inhibitors
of AQP3. Furthermore, the compounds’ antiproliferative effects have been studied in a small panel of
human cancer cells expressing AQP3. The complexes show only very moderate anticancer effects
in vitro and are mostly active against the melanoma A375 cells, with marked expression of AQP3 at
the level of the nuclear membrane. In general, the AQP3 inhibition properties of these complexes
hold promises to develop them as chemical probes to study the function of this protein isoform in
biological systems.
Keywords: Gold(III) complexes; pyridine benzimidazole; aquaporins; cancer; stopped-flow
spectroscopy; antiproliferative activity
1. Introduction
The severe side effects associated with chemotherapy necessitate the development of improved
anticancer therapies. Specifically, the discovery of compounds that can disrupt cancerous cellular
machinery by novel mechanisms of action is nowadays the focus of intense research. For example,
metal-based compounds acting via the interaction with proteins and secondary DNA structures, as well
as by alteration of the intracellular redox balance, have become prominent experimental therapeutic
agents. Among them, gold complexes have attracted attention in the last years and numerous families
of Au(I) and Au(III) compounds have been synthesized and studied for their anticancer properties
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in vitro and in vivo [1,2]. Overall, the investigation of the cytotoxic activity and related mode of action
of cytotoxic gold-based complexes has enabled the identification of their preferential “protein targets”,
as it is increasingly evident that DNA is not the unique or major target for such compounds [3]. In this
context, coordination cytotoxic Au(III) compounds have been identified as selective inhibitors of the
membrane water channels aquaporins (AQPs) [1,4].
Among the 13 mammalian AQPs described so far, three sub-groups can be recognized based
on permeability features: orthodox aquaporins (AQP0, AQP1, AQP2, AQP4, AQP5, AQP6 and AQP8),
which are primarily water selective and facilitate water movement across cell membranes in response to
osmotic gradients [5]; aquaglyceroporins (AQP3, AQP7, AQP9 and AQP10), facilitating the permeation
of small uncharged solutes such as glycerol [6]; and unorthodox aquaporins (AQP11, AQP12), found in
intracellular membranes and with reported permeability to water and glycerol [7–9]. Specifically,
the aquaglyceroporins regulate the glycerol content in the epidermis, fat and other tissues and appear
to be involved in skin hydration, cell proliferation, fat metabolism, and carcinogenesis. Several studies
showed that AQPs are closely associated with cancer proliferation and invasion, and are expressed in
at least 20 human cancers [10]. Moreover, AQPs expression is related to tumour types, grades,
proliferation, migration and angiogenesis, rendering these transport proteins attractive as both
diagnostic and therapeutic targets in cancer [10]. To validate the various roles of AQPs in health
and disease, and to develop AQP-targeted therapies, the use of selective inhibitors in addition to
genetic approaches, holds great promise. However, so far, no reported organic small-molecule AQPs
inhibitor possesses sufficient isoform selectivity to be a good candidate for clinical development [11].
A few years ago, we reported on the potent and selective inhibition of human AQP3 by a series of
Au(III) complexes with bidentate NˆN ligands [12,13], which could potently and selectively inhibit
glycerol permeation through hAQP3 in human red blood cells (hRBC). The most effective inhibitor of
the series, Auphen ([Au(phen)Cl2]Cl, phen = 1,10-phenanthroline) had an IC50 of 0.8 ± 0.08 µM [12].
In a further study, Auphen’s capacity of inhibiting cell proliferation was examined in various cell lines,
including cancerous ones, with different levels of AQP3 expression, and showed a direct correlation
between AQP3 expression levels and the inhibition of cell growth by the Au(III) compound [14].
AQP3 inhibition was also demonstrated in the cell lines where proliferation was mostly affected by
treatment with the gold complex [14]. Structure–activity relationships to optimize the design of AQP3
inhibitors were then established investigating other Au(III) compounds with different NˆN ligand
scaffolds [13].
Pursuing the design of more potent and selective AQP3 inhibitors, we have recently observed that
the cationic complex [Au(pbzMe)Cl2]PF6 (C1, pbzMe = 1-methyl-2-(pyridin-2-yl)-benzimidazole)
is even more efficient than Auphen in inhibiting glycerol permeation via AQP3 [1], and ca.
three orders of magnitude more effective than the neutral related complex [Au(pbzH)Cl2]
(C10, pbzH = 2-(pyridin-2-yl)-benzimidazole) [15]. Combined molecular dynamics (MD) and density
functional theory (DFT) studies were able to show that C1, upon binding to Cys40 in AQP3, is able to
induce protein conformational changes, leading to the shrinkage of the channel, and thus, preventing
glycerol and water permeation [15].
Following these promising results, we have synthesized a new series of Au(III) complexes based
on the 2-(2-pyridyl)benzimidazole (pbzH) N-donor ligand, which is also known to inhibit hepatic
enzymes, [16] and exhibits anticancer activities per se [17]. In general, metal complexes based on
2-(2′-pyridyl)benzimidazole scaffolds have attracted attention in various established and potential
application areas, including medicinal inorganic chemistry [18–20]. Thus, we report here on the
synthesis and characterization of eight new cationic Au(III) derivatives with functionalization at the
non-coordinated benzimidazole nitrogen. In addition, two neutral complexes featuring extended
aromatic scaffolds (namely pyrene and anthracene), endowed with luminescence properties, have been
obtained. The compounds have been tested for their AQPs inhibition properties in human Red Blood
Cells (hRBC) using a stopped-flow method, and their effects compared to C1 [Au(pbzMe)Cl2]PF6 and
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C10 [Au(pbzH)Cl2]. Furthermore, the compounds’ antiproliferative effects have been studied in a
small panel of human cancer cells with different levels of AQP3 expression.
2. Results
2.1. Synthesis and Characterization of Au(III) Complexes
The library of functionalised pyridylbenzimidazole ligands L1–L9 has been obtained by
nucleophilic substitution on the non-coordinated nitrogen atom of the commercially available
pyridylbenzimidazole by reaction with a halogenated substituent (R–X) in the presence of a base
(Scheme S1, Supplementary Materials) [21]. Several types of functional groups have been envisaged
to study the influence of both the steric hindrance and the electronic effect on the biological
properties of the final gold complexes. In parallel, two additional ligands (L11–L12) featuring
luminescent properties [22] have also been synthesized with the idea to monitor their fate in cancer
cells by fluorescence microscopy (Scheme S1, supplementary materials). The use of ligands L1–L9,
which possess a functionalised amine, gives rise to Au(III) cationic complexes (corresponding C1–C9)
by reaction between an equimolar amount of L1–L9 and NaAuCl4, in the presence of an excess
of KPF6 (Scheme 1, top). The pure cationic gold complexes can then easily be isolated following
precipitation, washing and filtration. On the other hand, reaction between ligands L10–L12 and
NaAuCl4 in the presence of a base leads to the formation of the neutral complexes C10–C12 (Scheme 1,
bottom) [15]. The identity and the purity of the complexes C1–C12 was confirmed by NMR, IR and
UV–Visible spectroscopies, as well as by mass spectrometry and in some cases by elemental analysis
(See Experimental and Supplementary Materials for details, Figures S1–S24). The obtained results
confirmed the purity of the compounds, which were all obtained in good yields. While all ligands were
found to be soluble in most organic solvents, and thus, their NMR analysis was performed in CDCl3,
the complexes were insoluble in most cases, except in rare examples in acetone or acetonitrile. To ensure
a similar analysis for all complexes, their NMR spectra were recorded in DMSO-d6. The 1H NMR
spectra of the ligands were easily attributable and the most downfield shifted signals corresponded to
the benzimidazole ring. In most cases, the signals of the protons of the pyridyl were found overlapping
each other, in addition to the signals of the phenyl rings for the R substituents in the case of L4–L9.
The 1H NMR spectra of the complexes were similar to those of the corresponding ligands in terms of
number of resonance signals; however, some signals (Ha, Hc and Hh, see Scheme 2 for the numbering
scheme) were clearly more affected by the presence of the Au(III)Cl2 fragment [∆δ (δcoord − δfree)
of 0.24 and 0.47 ppm]. The NMR analysis of both the ligands L11–L12 and their corresponding
complexes C11 and C12 was very challenging due to the electronic similarity and thus proximity on
the spectra. However, the number and nature of the signals were compatible with the structures,
and further analytical methods allowed us to confirm the purity of the compounds (ESI-MS, UV–Visible
spectroscopy and IR). IR analysis of the complexes showed in all cases the presence of C=C bending,
C–H stretching and C–N stretching bands, and confirmed the presence of specific chemical groups
on the main scaffold: alkyl chains in the case of C1–C3, ester group in the case of C5 and C–F bonds
for C6–C9.
Crystals suitable for X-ray diffraction were obtained for complex C6 by slow diffusion of
pentane in a concentrated solution of the complex in a mixture of acetonitrile and dichloromethane
at room temperature (see Supplementary Materials for details). The structure confirmed a bidentate
coordination mode of the ligand L6 onto the gold centre via the nitrogen of the pyridine and the
benzimidazole rings, giving rise to square planar complexes. The 4-trifluoromethylbenzyl functional
group added on the benzimidazole moiety always points out of the plane, as already described
with similar ligands and copper complexes [18]. It is worth mentioning that the slow process of
crystallisation (10–15 days) may favour the partial decomposition of the complexes, specifically the
de-coordination of the gold centre and the exchange of counter anions. In fact, the structure
of C6 revealed the presence of AuCl4 counterions in the lattice (see Supplementary Materials).
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Furthermore, we attempted to crystallize compound C7 in the same conditions, but the resulting
X-ray structure confirmed the de-coordination of the gold centre from one of the nitrogens of the
pyridine ligand, thus leading to a neutral gold complex with three coordinated chlorido ligands
(see supplementary materials).
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The complexes C1–C12 and their corresponding ligands L1–L12 have also been investigated for
their photophysical properties (see Figures S25–S48). Both ligands L1–L10 and complexes C1–C9
exhibit a strong absorption band centred around 310–315 nm which can be attributed to pi→pi*
transitions and/or ligand-to-metal charge transfers (LMCT) in the case of the Au(III) complexes.
The absorption spectra of ligands L11–L12 and corresponding complexes C11–C12, with the extended
conjugated systems, show several bands attributed to the same transitions between 330 and 390 nm.
Ligands L1–L10 and complexes C1–C9 all have single fluorescence emission bands centred around
375–380 nm, representing a Stokes shift of about 65 nm. Complexes C11–C12 and their corresponding
ligands possess extended aromatic and conjugated systems; thus, a shift in the emission bands is
observed: ligand L11 and complex C11 emit at 415 nm whereas L12 and C12 exhibit an emission band
around 450 nm (Figures S45–S48). The quantum yield of fluorescence (ΦF) has also been assessed for
all the reported compounds (see Figures S25–S48). While the ligands with the alkane substituents
(L1–L3) have relatively high quantum yields (50–60%), the ligands with the functionalised benzyl
groups (L4–L9) have decreased quantum yields between 27 and 42%. The ligands with the extended
aromatic systems L11 and L12 have quantum yields of 74 and 61%, respectively (Figures S45 and S47).
In general, upon coordination of the ligands to the gold(III) ion, almost all quantum yields of
luminescence are decreased due to the “heavy metal effect”, with the exception of complex C12
(ΦF = 71%).
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2.2. UV–Visible Stability Studies
The stability of the gold complexes was investigated using UV–Visible spectroscopy before
further biological testing. Thus, the absorbance of the compounds’ solutions in PBS buffer (pH 7.4)
was measured between 300 and 800 nm at regular time intervals during 24 h at room temperature,
allowing the monitoring of possible compound’s transformations such as hydrolysis, reduction and/or
precipitation. In parallel, as Au(III) complexes tend to be reduced in physiological conditions to Au(I)
and even Au(0), the reactivity of the compounds with the intracellular reducing agent glutathione
(GSH) was monitored in the same conditions.
All the Au(III) compounds exhibit intense transitions in the 300–400 nm range, characteristic of the
Au(III) chromophore, that may be straightforwardly assigned as LMCT bands. Complexes C1, C2, C5,
C6 and C9 were found to be mostly stable over the first 6 h in PBS buffer (pH 7.4) with no significant
change in the UV–Visible spectra (Figures S49, S50, S53, S54 and S57). The observed small spectral
changes developing with time might be related to the occurrence of partial hydrolysis processes.
Instead, the spectra of complexes C3, C4, C7, C8 and C10 were found to undergo major changes over
the first few hours (Figures S51–S52, S55–S56 and S58), leading to the disappearance of the classical
LMCT bands, suggesting disruption of the Au(III) complex. Complexes C11–C12 were moderately
stable in solution (Figures S59 and S60) featuring hypocromic shifts in their spectra over the first 6 h of
incubation. In the presence of GSH, all the compounds immediately reacted to form adducts leading
to the loss of the N-donor ligands from the gold centre, as demonstrated by the disappearance of the
LMCT bands (Figures S49–S58). Only compounds C11 and C12 were scarcely reactive and maintained
their spectral features over time after the addition of GSH (Figures S59 and S60).
2.3. Inhibition of Aquaporins
Based on the previosuly discussed stability studies, only the most stable gold complexes were
tested for their AQP1 and AQP3 inhibition properties in hRBC by stopped-flow spectroscopy, according
to previously reported procedures [12]. A representative IC50 curve for the inhibition of glycerol
permeation via AQP3 by two gold compounds is reported in Figure 1. The obtained results are
summarized in Table 1 and show that all the new cationic complexes C2, C4, C5, C6, C9 and C11
are able to selectively inhibit glycerol permeation via AQP3, with IC50 values in the sub-micromolar
level, comparable to C1 and Auphen. The antiproliferative activities of the corresponding ligands
are presented in the supplementary (Table S1). The most effective compound was C6. In line with
previous results, the neutral compound C10 was ca. one order of magnitude less effective as an AQP3
inhibtior [15]. Of note, all the compounds were inactive as inhibitors of the orthodox water channel
AQP1 in the same cellular model (data not shown).
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Table 1. AQP3 inhibitory effects (IC50 values) measured in hRBC after 30 min incubation;
and antiproliferative activities (EC50 values) of Au(III) compounds in human SKOV-3, A375, MCF-7,
and A549 cells after 72 h incubation, measured by the MTT assay.
Compound AQP3 Inhibition EC50 [µM]
1
IC50 [µM] 1 SKOV-3 A375 MCF7 A549
Auphen 0.80 ± 0.08 7.00 ± 2.00 1.7 ± 0.3 3.00 ± 0.05 1.07 ± 0.09
C1 1.018 ± 0.137 >80 >80 >80 >80
C2 0.881 ± 0.015 >80 >80 >80 >80
C3 1.825 ± 0.017 (n = 2) 41 ± 13 23 ± 1 40 ± 4 57 ± 2
C4 0.85 ± 0.21 56 ± 12 69 ± 3 63 ± 1 81 ± 9
C5 0.80 ± 0.10 >50 >50 25 (n = 1) >50)
C6 0.69 ± 0.06 >50 34 (n = 1) 38 (n = 1) 47 (n = 2)
C7 n.d. n.d. n.d. n.d. n.d.
C8 n.d. n.d. n.d. n.d. n.d.
C9 0.72 ± 0.05 >50 >50 >50 >50
C10 >50 17 ± 7 5 ± 2 12 ± 1 >50
C11 0.82 ± 0.13 (n = 2) 33 ± 5 12 ± 2 29 ± 8 >50
C12 n.d. 41 ±13 13 ± 2 17 ± 3 45 ± 3
1 Values represented as mean (±SEM) of at least three independent experiments (n), unless otherwise stated.
n.d. = non determined.
2.4. Expression of AQP3 in Cancer Cells and Antiproliferative Activities
Afterward, the compounds—with the exception of the highly unstable C7 and C8—were
evaluated for their antiproliferative activities against a panel of human cancer cells in vitro. The cells
were selected and studied for their level of expression of human AQP3. Information on the expression
of AQP3 in cancer lines is limited and most of the data currently available refers to mRNA expression
levels [23]. Specifically, cells were studied for the expression levels of human AQP3 by flow cytometry
(Figure S61) and their AQP3 cellular distribution by immunocytofluorescence, respectively (Figure 1).
As expected from the literature and mRNA levels [23], the breast cancer cell line MCF-7 highly express
AQP3. Ovarian cancer cells SKOV-3 also showed marked AQP3 expression, followed by the lung
cancer cells A549 and the skin malignant melanoma cells A375. Regarding cellular localization, in the
case of the melanoma cells A375, AQP3 was found to be also localized in the nuclear membrane
(Figure 2) as evidenced by fluorescence microscopy.
The antiproliferative activities of the complexes are summarized in Table 1. Overall, the compounds
show very moderate anticancer effects in all cell lines, with compounds C1 and C2 being the least toxic
(EC50 > 80 µM). Compounds C3 and C4 were moderately cytotoxic, but their scarce stability in the
aqueous environment may affect their antiproliferative effects. Compounds C10–C12 were the most
effective in the series, particularly against the melanoma A375 cells. It is worth mentioning that these
three compounds are the only neutral ones, and may display different uptake and accumulation in
cancer cells with respect to the cationic derivatives. Of note, the ligands L1–L12 generally showed
reduced antiproliferative effects with respect to the corresponding gold complexes (Table S1).
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DecaXPPlus quadrupole ion-trap instrument (Thermo Fisher Scientific, Paisley, UK) operated in 
positive ion mode over a mass range of m/z 150–2000. IR spectra were measured on a Shimadzu 
IRAffinity-1S FT-IR (ATR) (Shimadzu, Milton Keynes, UK). Ligand functionalization reactions were 
monitored by thin-layer chromatography (Merck 60 F254 silica gel). Column chromatography was 
carried out manually using silica gel (Fluorochem; 40–63 μm, 60 Å) or on a Biotage Isolera 
automated flash purification system (ZIP cartridge, 5–10 g). The absorption and emission spectra of 
the ligands and corresponding complexes were recorded on Cary 5000 or 60 UV–Visible NIR 
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Figure 2. Human AQP3 expression and localization in human cancer cells by immunocytofluorescence.
Hu an AQP3 expression (green) in A549, A375, SKOV-3 and MCF-7 cancer cells, with nuclei stained
with DAPI (blue). Scale bars represent 25 µm.
3. aterials a et s
3.1. General Information
All reagents and solvents used have been obtained from Haereus (Hanau, Germany),
Sigma Aldrich (St. Louis, MO, United States), Fluorochem (Old Glossop, UK), Alfa Aesar (Ward
Hill, MA, USA) or Acros (Loughborough, UK) and were used as received unless specified. The identity
and purity (≥95%) of the complexes were unambiguously established using high-resolution mass
spectrometry and multinuclear NMR spectroscopy. 1H, 13C and 19F NMR spectra were recorded on a
Bruker Avance II300, II400 or II500 spectrometers (Bruker, Coventry, UK) at room temperature (r.t.)
and referenced internally to residual solvent peaks [24]. The coupling constants are reported in Hertz.
HR-ESI-MS spectra were obtained in acetonitrile/methanol on a Thermo Finnigan LCQ DecaXPPlus
quadrupole ion-trap instrument (Thermo Fisher Scientific, Paisley, UK) operated in positive ion mode
over a mass range of m/z 150–2000. IR spectra were measured on a Shimadzu IRAffinity-1S FT-IR (ATR)
(Shimadzu, Milton Keynes, UK). Ligand functionalization reactions were monitored by thin-layer
chromatography (Merck 60 F254 silica gel). Column chromatography was carried out manually
using silica gel (Fluorochem; 40–63 µm, 60 Å) or on a Biotage Isolera automated flash purification
system (ZIP cartridge, 5–10 g). The absorption and emission spectra of the ligands and corresponding
complexes were recorded on Cary 5000 or 60 UV–Visible NIR (Agilent, Wokingham, UK), Cary Eclipse
Fluorescence spectrophotometers (Agilent).
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3.2. Compounds Synthesis
3.2.1. General Procedure for the Synthesis of Ligands L1–L9
Pyridylbenzimidazole ligand L10 is commercially available. Functionalised pyridylbenzimidazole
derivatives L1 [21], L4 [25], L7 [22], L8 [22], L9 [22], L11 [25], and L12 [18] have been synthetized
following protocols reported in the literature. Ligands L2 and L3 have been obtained adapting
protocols used to produce L1 and L4, and have also been already reported in the literature [26].
The purity of the compounds was confirmed by elemental analysis, and all of them showed purity
greater than 98%. Compounds L5 and L6 have been obtained using the following general protocol:
A solution of 1 eq. of pyridylbenzimidazole (488 mg, 2.50 mmol) and 1.5 eq. of K2CO3 (518 mg,
3.75 mmol) in 5 mL of DMF was stirred at room temperature for 30 min. Then, 1.2 eq. (3.00 mmol) of
methyl-4-(bromomethyl)benzoate (in the case of L5; 687 mg) or 4-(trifluoromethyl)benzyl bromide
(in the case of L6; 717 mg) were added to the mixture and left to stir at room temperature for
approximately 4 h (the reaction was followed by TLC using a 1:1 ethyl acetate/hexane eluent system).
The solution was then concentrated and water was added. The product was extracted several times by
ethyl acetate. Organic layers were combined, washed with water and dried over MgSO4. After filtration
and evaporation of the solvent, the crude products L5 and L6 were obtained and purified by column
chromatography either manually using a 1:1 mixture of ethyl acetate and hexane or on an automated
flash purification system using a gradient of ethyl acetate in hexane.
L5. White powder, 83% isolated yield (712 mg, 2.07 mmol). Rf (1:1 AcOEt/hexane) ≈ 0.6.
NMR 1H (CDCl3): 8.56 (ddd, J = 7.9, 4.0 and 2.7 Hz, 1H, Ha), 8.44 (dt, J = 8.0 and 1.0 Hz, 1H,
Hd), 7.92–7.87 (m, 3H, 2xCH–Ph + He), 7.81 (td, J = 8.0 and 1.8 Hz, 1H, Hc), 7.33–7.25 (m, 5H,
Hh + Hb + Hf + Hg + He), 7.20 (d, J = 8.5 Hz, 2H, 2xCH–Ph), 6.14 (s, 2H, CH2), 3.77 (s, 3H, CH3).
NMR 13C{1H} (CDCl3): 166.8 (CO2Me), 150.4 (CIV), 149.9 (CIV), 148.7 (Ca), 142.8 (CIV), 142.8 (CIV),
137.0 (Cc), 136.8 (CIV), 130.0 (2xCH–Ph), 129.3 (CIV), 126.7 (2xCH–Ph), 124.7 (Cd), 124.0, 123.9,
123.0 (Cb, Cf, Cg), 120.3 (Ce), 110.5 (Ch), 52.2 (CH3), 48.9 (CH2). ESI-TOF-MS (positive mode) for
C21H18N3O2 ([M + H]+): calc. 344.1399, exp. 344.1404 (err. 1.5 ppm). UV–Vis (DMSO): λmax (nm)
(ε, cm−1·mol−1·dm3) 313 (14,123). IR (ATR): ν (cm−1) 1709 (νC–H bending), 1428 (νC–H stretching),
1276 (νC–O stretching), 1110 (νC–N stretching), 845 (νC=C bending). Anal. Calcd for C21H17N3O2 (343.39):
C, 73.45; H, 4.99; N, 12.24. Found: C, 73.48; H, 4.97; N, 12.20.
L6. White powder, 88% isolated yield (774 mg, 2.19 mmol). Rf (1:1 AcOEt/hexane) ≈ 0.6. NMR
1H (CDCl3): 8.55 (m, 1H, Ha), 8.44 (d, J = 8.0 Hz, 1H, Hd), 7.84 (d, J = 7.8 Hz, 1H, He), 7.79 (td, J = 7.8
and 1.8 Hz, 1H, Hc), 7.46 (d, 2H, 2xCH–Ph), 7.47–7.22 (m, 6H, 2xCH–Ph + Hh + Hb + Hf + Hg),
6.20 (s, 2H, CH2). NMR 13C{1H} (CDCl3): 150.4 (CIV), 149.8 (CIV), 148.7 (Ca), 142.8 (CIV), 141.7 (CIV),
137.1 (Cc), 136.7 (CIV), 129.7 (q, CIV–CF3, 2JC–F = 32.0 Hz), 126.8 (2xCH–Ph), 125.7 (q, 2xCH–C–CF3,
3JC–F = 3.8 Hz), 124.7 (Cd), 124.2 (q, CIVF3, 1JC–F = 270 Hz), 124.1, 123.9, 123.2 (Cb, Cf, Cg), 120.4 (Ce),
110.4 (Ch), 48.7 (CH2). NMR 19F{1H} (CDCl3): −62.5 (s, CF3). ESI-TOF-MS (positive mode) for
C20H15N3F3 ([M + H]+): calc. 354.1218, exp. 354.1225 (err. 2.0 ppm). UV–Vis (DMSO): λmax (nm)
(ε, cm−1·mol−1·dm3) 313 (23,130). IR (ATR): ν (cm−1) 1444 (νC–H stretching), 1328, 1157 (νC–F stretching),
1107 (νC–N stretching), 833 (νC=C bending). Anal. Calcd for C20H14N3F3 (353.11): C, 67.98; H, 3.99; N, 11.89.
Found: C, 67.95; H, 3.93; N, 11.82.
3.2.2. General Procedure for the Synthesis of the Cationic Complexes C1–C9
Complex C1 was previously reported by us [15], and the same procedure was used to obtain
complexes C2–C9. Thus, to a solution of 1 eq. of pyridylbenzimidazole ligand L1–L9 in acetonitrile
(2.5 mL) was added an aqueous solution (15 mL) of 1 eq. of NaAuCl4 and 3 eq. of KPF6, and the
resulting mixture was stirred 3 h at room temperature. The resulting yellow to orange precipitate was
filtered, washed with water, ethanol and diethyl ether and dried under vacuum.
C2. Yield: 68% (480 mg, 0.76 mmol). NMR 1H (DMSO-d6): 8.93 (m, 1H, Ha), 8.29 (m, 1H, Hd), 8.21
(m, 1H, Hc), 8.05 (m, 1H, He), 7.89 (m, 1H, Hh), 7.76 (m, 1H, Hb), 7.61 (m, 2H, Hf + Hg), 4.87 (m, 2H, CH2),
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1.50 (s, 3H, CH3). NMR 13C{1H} (DMSO-d6): 150.2 (Ca), 146.8 (CIV), 144.3 (CIV), 138.3 (Cc), 133.3 (2xCIV),
128.0 (Cg), 127.6 (Cf), 126.0 (Cd), 125.8 (Cb), 115.8 (Ch), 112.9 (Ce), 41.4 (CH2), 14.9 (CH3). ESI-TOF-MS
(positive mode) for C14H13N3Cl2Au ([M+]): calc. 490.0152, exp. 490.0134 (err. −3.7 ppm). UV–Vis
(DMSO): λmax (nm) (ε, cm−1·mol−1·dm3) 313 (21,654). IR (ATR): ν (cm−1) 1475, 1457 (νC–H stretching),
1036 (νC–N stretching), 841, 749 (νC=C bending).
C3. Yield: 89% (561 mg, 0.78 mmol). NMR 1H (DMSO-d6): 8.92 (m, 1H, Ha), 8.29–8.19 (m, 2H,
Hd + Hc), 8.08 (m, 1H, He), 7.90 (m, 1H, Hh), 7.78 (m, 1H, Hb), 7.66–7.58 (m, 2H, Hf + Hg), 4.85 (m, 2H,
CH2), 1.85 (m, 2H, CH2), 1.17 (m, 10H, CH2), 0.82 (m, 3H, CH3). NMR 13C{1H} (DMSO-d6): 150.3 (Ca),
146.9 (CIV), 143.9 (CIV), 138.8 (Cc), 136.9 (CIV), 133.6 (CIV), 127.5 (Cg), 127.1 (Cf), 126.7 (Cd), 126.6 (Cb),
115.7 (Ch), 113.8 (Ce), 46.3 (CH2), 31.6 (CH2), 29.5 (CH2), 28.9 (CH2), 28.8 (CH2), 26.2 (CH2), 22.5 (CH2),
14.4 (CH3). ESI-TOF-MS (positive mode) for C20H25N3Cl2Au ([M+]): calc. 574.1091, exp. 574.1100
(err. 1.6 ppm). UV–Vis (DMSO): λmax (nm) (ε, cm−1·mol−1·dm3) 312 (16,006). IR (ATR): ν (cm−1) 2927
(νC–H stretching), 1488, 1474 (νC–H stretching), 1039 (νC–N stretching), 831, 746 (νC=C bending).
C4. Yield: 99% (403 mg, 1.61 mmol). NMR 1H (DMSO-d6): 8.83 (m, 1H, Ha), 8.30 (m, 1H, Hd), 8.17
(m, 1H, Hc), 7.87 (m, 1H, He), 7.78 (m, 1H, Hh), 7.70 (m, 1H, Hb), 7.55–7.49 (m, 2H, Hf + Hg), 7.29–7.25
(m, 5H, 5xCH–Ph), 6.21 (s, 2H, CH2). NMR 13C{1H} (DMSO-d6): 149.9 (Ca), 147.2 (CIV), 144.5 (CIV),
138.1 (Cc), 135.5 (CIV), 133.7 (CIV), 128.6 (CH–Ph), 127.7 (CH–Ph), 126.9 (Cb), 126.5 (Cd), 125.7 (Cf),
125.7 (Cg), 116.1 (Ce), 113.0 (Ch), 48.7 (CH2). ESI-TOF-MS (positive mode) for C19H15N3Cl2Au ([M+]):
calc. 552.0309, exp. 552.0307 (err. −0.4 ppm). UV–Vis (DMSO): λmax (nm) (ε, cm−1·mol−1·dm3)
313 (21,527). IR (ATR): ν (cm−1) 1497, 1475, 1454 (νC–H stretching), 831, 746 (νC=C bending).
C5. Yield 48% (265 mg, 0.351 mmol). NMR 1H (DMSO-d6): 8.80 (m, 1H, Ha), 8.31 (m, 1H,
Hd), 8.17 (t, J = 5.7 Hz, 1H, Hc), 7.92–7.88 (m, 3H, 2xCH–Ph + He), 7.77 (m, 1H, Hh), 7.69 (m, 1H,
Hb), 7.58–7.50 (m, 2H, Hf + Hg), 7.41–7.39 (m, 2H, 2xCH–Ph), 6.30 (s, 2H, CH2), 3.80 (s, 3H, CH3).
NMR 13C{1H} (DMSO-d6): 165.9 (CO2Me), 149.9 (Ca), 145.0 (CIV), 141.3 (CIV), 138.3 (Cc), 134.5 (CIV),
129.5 (CH–Ph), 129.1 (CIV), 127.3 (CH–Ph), 126.6 (Cb), 125.9 (Cf+g), 125.7 (Cd), 116.5 (Ce), 112.9 (Ch),
52.2 (CH3), 48.8 (CH2). ESI-TOF-MS (positive mode) for C21H17N3O2Cl2Au ([M+]): calc. 610.0363,
exp. 610.0350 (err. −2.1 ppm). UV–Vis (DMSO): λmax (nm) (ε, cm−1·mol−1·dm3) 312 (23,448). IR (ATR):
ν (cm−1) 1706 (νC–H bending), 1496, 1481 (νC–H stretching), 1285, 1018 (νC–O stretching), 1108 (νC–N stretching),
845 (νC=C bending).
C6. Yield: 99% (435 mg, 0.568 mmol). NMR 1H (DMSO-d6): 8.81 (d, J = 4.3 Hz, 1H, Ha), 8.32
(d, J = 7.8 Hz, 1H, Hd), 8.18 (td, J = 7.8 and 1.3 Hz, 1H, Hc), 7.92 (d, 1H, J = 7.7 Hz, He), 7.80
(d, 1H, J = 7.8 Hz, Hh), 7.72–7.68 (m, 3H, Hb + 2xCH–Ph), 7.59–7.53 (m, 2H, Hf + Hg), 7.52–7.49
(m, 2H, 2xCH–Ph), 6.31 (s, 2H, CH2). NMR 13C{1H} (DMSO-d6): 150.2 (Ca), 147.3 (CIV), 143.9 (CIV),
140.3 (CIV), 138.5 (Cc), 133.6 (CIV), 132.9 (CIV), 128.2 (q, CIV–CF3, 2JC–F = 31.5 Hz), 127.9 (2xCH–Ph),
127.0 (Cb), 126.6 (Cf), 126.4 (Cg), 126.0 (Cd), 125.6 (q, 2xCH–C–CF3, 3JC–F = 3.9 Hz), 123.8 (q, CIVF3,
1JC–F = 272 Hz), 115.9 (Ce), 113.2 (Ch), 48.8 (CH2). NMR 19F{1H} (DMSO-d6): −61.0 (s, CF3), −70.0
(d, PF6, 1JP–F = 712.4 Hz). ESI-TOF-MS (positive mode) for C20H14N3Cl2F3Au ([M+]): calc. 620.0182,
exp. 620.0212 (err. 4.8 ppm). UV–Vis (DMSO): λmax (nm) (ε, cm−1·mol−1·dm3) 312 (24,699). IR (ATR):
ν (cm−1) 1481 (νC–H stretching), 1324, 1121, 1113 (νC–F stretching), 1068 (νC–N stretching), 834 (νC=C bending).
Anal. Calcd for C20H14N3Cl2AuPF9 (766.18): C, 31.35; H, 1.84; N, 5.48. Found: C, 31.35; H, 1.88; N, 5.48.
C7. Yield: 87% (312 mg, 0.436 mmol). NMR 1H (DMSO-d6): 8.82 (d, J = 4.2 Hz, 1H, Ha), 8.31
(d, J = 8.0 Hz, 1H, Hd), 8.15 (t, J = 7.6 Hz, 1H, Hc), 7.86 (d, 1H, J = 7.6 Hz, He), 7.78 (d, 1H, J = 7.1 Hz,
Hh), 7.88 (t, 1H, J = 5.3 Hz, Hb), 7.50 (m, 2H, Hf + Hg), 7.35–7.32 (m, 2H, 2xCH–Ph), 7.15–7.11 (m, 2H,
2xCH–Ph), 6.19 (s, 2H, CH2). NMR 13C{1H} (DMSO-d6): 162.9 (CIV), 160.5 (CIV), 150.0 (Ca), 147.4 (CIV),
144.6 (CIV), 138.3 (Cc), 133.9 (CIV), 133.0 (d, CIVF, 1JC–F = 203 Hz), 129.4 (d, 2xCH–Ph, 3JC–F = 8.4 Hz),
126.7 (Cb), 126.0 (Cf), 126.0 (Cg), 125.9 (Cd), 116.3 (Ce), 115.6 (d, 2xCH–Ph, 2JC–F = 21.5 Hz), 113.1
(Ch), 48.2 (CH2). NMR 19F{1H} (DMSO-d6): −114.3 (s, Ph–F), −70.0 (d, PF6, 1JP–F = 711.9 Hz).
ESI-TOF-MS (positive mode) for C19H14N3Cl2FAu ([M+]): calc. 570.0214, exp. 570.0236 (err. 3.9 ppm).
UV–Vis (DMSO): λmax (nm) (ε, cm−1·mol−1·dm3) 312 (25,542). IR (ATR): ν (cm−1) 1460 (νC–H stretching),
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1232 (νC–F stretching), 835 (νC=C bending). Anal. Calcd for C18H12N3O2Cl2AuPF7 (702.14): C, 31.86; H,
1.97; N, 5.87. Found: C, 31.82; H, 2.00; N, 5.88.
C8. Yield: 99% (394 mg, 0.500 mmol). NMR 1H (DMSO-d6): 8.76 (d, J = 4.4 Hz, 1H, Ha), 8.31
(d, J = 7.9 Hz, 1H, Hd), 8.14 (td, J = 7.8 and 1.6 Hz, 1H, Hc), 7.90–7.86 (m, 2H, Hh + He), 7.66 (m, 1H,
Hb), 7.58–7.51 (m, 2H, Hf + Hg), 6.36 (s, 2H, CH2). NMR 13C{1H} (DMSO-d6): 149.3 (Ca), 148.5 (CIV),
146.7 (CIV), 146.0 (dd, CIVF, 1JC–F = 246 Hz), 138.3 (Cc), 137.1 (CIV), 135.2 (CIV), 126.0 (Cb), 125.4 (Cg),
125.3 (Cf), 125.0 (Cd), 117.9 (Ce), 112.1 (Ch), 110.9 (t, CIV–Ph, 2JC–F = 17 Hz), 39.9 (CH2). NMR 19F{1H}
(DMSO-d6): −141.9 (Ph–F),−154.3 (Ph–F),−162.4 (Ph–F),−70.0 (d, PF6, 1JP–F = 711.9 Hz). ESI-TOF-MS
(positive mode) for C19H10N3Cl2F5Au ([M+]): calc. 641.9837, exp. 641.9874 (err. 5.8 ppm). UV–Vis
(DMSO): λmax (nm) (ε, cm−1·mol−1·dm3) 311 (23,441). IR (ATR): ν (cm−1) 1474 (νC–H stretching), 1337,
1128 (νC–F stretching), 1029 (νC–N stretching), 838 (νC=C bending).
C9. Yield: 99% (443 mg, 0.603 mmol). NMR 1H (DMSO-d6): 8.82 (d, J = 4.2 Hz, 1H, Ha), 8.29
(d, J = 8.0 Hz, 1H, Hd), 8.20 (t, J = 7.6 Hz, 1H, Hc), 7.91 (d, 1H, J = 7.6 Hz, He), 7.78 (d, 1H, J = 7.1 Hz,
Hh), 7.88 (t, 1H, J = 5.3 Hz, Hb), 7.57 (m, 2H, Hf + Hg), 7.19–7.09 (m, 4H, 4xCH–Ph), 6.20 (s, 2H,
CH2). NMR 13C{1H} (DMSO-d6): 162.6 (d, CIVF, 1JC–F = 247 Hz), 162.4 (d, CIVF, 1JC–F = 247 Hz),
150.2 (Ca), 147.2 (CIV), 143.6 (CIV), 139.9 (t, CIVPh, 3JC–F = 9.6 Hz), 138.5 (Cc), 133.4 (CIV), 132.4 (CIV),
127.1 (Cb), 126.7, 126.5 (Cf, Cg), 126.1 (Cd), 115.7 (Ce), 113.2 (Ch), 110.6 (d, 2xCH–Ph, 2JC–F = 26.1 Hz),
103.5 (t, CH–Ph, 2JC–F = 25.8 Hz), 48.5 (CH2). NMR 19F{1H} (DMSO-d6): −109.1 (s, 2xPh–F), −70.0
(d, PF6, 1JP–F = 712.6 Hz). ESI-TOF-MS (positive mode) for C19H13N3Cl2F2Au ([M+]): calc. 588.0120,
exp. 588.0150 (err. 5.1 ppm). UV–Vis (DMSO): λmax (nm) (ε, cm−1·mol−1·dm3) 313 (14,367). IR (ATR):
ν (cm−1) 1442 (νC–H stretching), 1332, 1091 (νC–F stretching), 1039 (νC–N stretching), 833, 792 (νC=C bending).
3.2.3. General Procedure for the Synthesis of the Neutral Complexes C10–C12
The synthesis of complex C10 was already reported by us [15] and others [19], and was adapted
to the synthesis of C11 and C12. To a solution of 1 eq. of pyridylbenzimidazole ligand L10–L12 in
acetonitrile (1 mL) was added an aqueous solution of 1 eq. of KOH in water (6 mL). The reaction mixture
was stirred at room temperature for 15 min. An aqueous solution of 1 eq. of NaAuCl4 (6 mL) was then
added, and the resulting mixture was stirred overnight at room temperature. The resulting dark brown
precipitate was filtered; washed with water, ethanol and diethyl ether; and dried under vacuum.
C11. Yield: 57% (100 mg, 0.18 mmol). NMR 1H (500 MHz, DMSO-d6): 9.11–8.90 (m, 3H,
3xCH), 8.78 (m, 1H, CH), 8.42 (m, 2H, 2xCH), 8.21 (m, 1H, CH), 8.13 (m, 1H, CH), 7.86–7.74 (m, 3H,
3xCH), 7.67 (m, 1H, CH). NMR 13C{1H} (125.77 MHz, DMSO-d6): 160.8 (CIV), 150.3 (CH), 145.4 (CIV),
145.0 (CIV), 138.0 (CH), 134.9 (CIV), 128.8 (CH), 127.6 (CH), 127.4 (CH), 125.5 (CH), 124.6 (CH),
124.5 (CH), 123.4 (CH), 122.7 (CH), 122.5 (CH), 121.0 (CH), 120.4 (CH). ESI-TOF-MS (positive mode)
for C20H12N3ClAu ([M – Cl+]): calc. 526.0385, exp. 526.0386 (err. 0.2 ppm). UV–Vis (DMSO):
λmax (nm) (ε, cm−1·mol−1·dm3) 333 (20,891), 362 (16,528). IR (ATR): ν (cm−1) 1428, 1452 (νC–H stretching),
1034 (νC–N stretching), 774 (νC=C bending).
C12. Yield: 47% (87 mg, 0.15 mmol). NMR 1H (500 MHz, MeCN-d3): 8.63–8.47 (m, CH), 8.35
(m, CH), 8.27 (m, CH), 8.23 (m, CH), 8.14–7.98 (m, CH), 7.59–7.57 (m, CH). NMR 13C{1H} (125.77 MHz,
DMSO-d6): 161.2 (CIV), 150.4 (CH), 149.6 (CH), 145.7 (CIV), 145.5 (CIV), 138.0 (CH), 135.6 (CIV),
131.7 (CIV), 128.3 (CH), 127.8 (CH), 127.2 (CH), 126.6 (CH), 125.0 (CH), 124.5 (CIV), 123.4 (CH),
122.8 (CIV), 122.6 (CIV), 122.2 (CIV), 120.0 (CH), 119.7 (CH), 119.5 (CIV), 118.3 (CH). ESI-TOF-MS
(positive mode) for C22H12N3ClAu ([M − Cl+]): calc. 550.0385, exp. 550.0393 (err. 1.5 ppm). UV–Vis
(DMSO): λmax (nm) (ε, cm−1·mol−1·dm3) 338 (28,904), 353 (28,264), 366 (19,892), 388 (20,031). IR (ATR):
ν (cm−1) 1442 (νC–H stretching), 1064 (νC–N stretching), 738 (νC=C bending).
3.3. UV–Visible and Fluorescence Spectroscopy
The data are reported as the absorption maximum wavelength (λmax, in nm) and corresponding
molar extinction coefficient at λmax (ε, in L·mol−1·cm−1). Macro quartz cuvettes with a path length of
1 cm were used. The sample concentrations were chosen to obtain a maximum absorbance of around
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0.8 to then measure the quantum yields. Relative quantum yields of fluorescence of the samples were
obtained by comparing the areas under the corrected emission spectra with a standard absorbing in
the same region than the sample. Measurements were performed in degassed DMSO (Sigma-Aldrich,
spectroscopic grade ≥99.9%) at 298 K. Quinine sulfate (ΦF = 0.546 in 0.5 M H2SO4, λex = 366 nm) was
used as the standard [26]. In all ΦF calculations, the correction for the solvent refractive index (η)
was applied: DMSO: η = 1.479; H2O (or H2SO4): η = 1.333 [27]. The following equation was used to
calculate the quantum yield of the sample (ΦF,x), in which ΦF,St is the reported quantum yield of the
standard, F is the integral photon flux, f is the absorption factor, and η is the refractive index of the
solvent used. The x subscript denotes the sample, and St denotes the standard, and the fluorescence
spectra between the sample and the standard were recorded at the same λex [28]:
φF,x = φF,St .
Fx
FSt
.
fSt
fx
.
η2x
η2St
3.4. X-ray Diffraction Analysis
Complexes C6 and C7 were allowed to form crystals by slow diffusion of pentane into a
corresponding complex’s concentrated solution in a mixture of acetonitrile and dicholoromethane
at room temperature. The crystals were analysed at the UK National Crystallography Service in
Southampton [29]. A suitable yellow block-shaped crystal from C6 (0.050 × 0.040 × 0.030) mm3
and from C7 (0.080 × 0.050 × 0.020) mm3, were selected and mounted on a MITIGEN holder in
perfluoroether oil and mounted on a Rigaku 007HF diffractometer equipped with Varimax confocal
mirrors and an AFC11 goniometer and HyPix 6000HE detector. The crystals were kept at T = 100.00(10)
K during data collection. Using Olex2 [30], the structures were solved with the ShelXT [31] structure
solution program, using the Intrinsic Phasing solution method. The models were refined with version
2014/7 of ShelXL [32] using Least Squares minimisation, and the ORTEP views are presented in
Figures S62 and S63. (CCDC 1868645 and 1868642 contain the supplementary crystallographic data for
this paper. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/conts/retrieving.
html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; Fax: +44 1223 336033; E-mail:
deposit@ccdc.cam.ac.uk)).
3.5. UV–Visible Absorption Spectroscopy
The new Au(III) complexes were tested for their stability in aqueous media (1× Phosphate Buffer
Saline (PBS, Corning), pH 7.4) in the presence or absence of 2 eq. GSH (vs. 1 eq. of Au(III) complex).
The solutions were prepared from a stock solution of the Au(III) complex at a concentration of 10−2 M
in DMSO and diluted to reach a concentration of 10−4 M in PBS. The absorption spectra were recorded
over time at room temperature using a Cary 500 UV–Visible NIR spectrophotometer.
3.6. Aquaporins Inhibition
Venous blood samples were obtained from healthy human volunteers following a protocol
approved by the Ethics Committee of the Faculty of Pharmacy of the University of Lisbon
(Instituto Português de Sangue Protocol SN-22/05/2007). Informed written consent was obtained
from all participants. Blood samples, collected in citrate anticoagulant (2.7% citric acid, 4.5% trisodium
citrate and 2% glucose), were centrifuged at 750× g for 5 min at 4 ◦C. Plasma and buffy coat were
discarded. Pelleted erythrocytes were washed three times in PBS (KCl 2.7 mM, KH2PO4 1.76 mM,
Na2HPO4 10.1 mM, NaCl 137 mM, pH 7.4), diluted to 0.5% haematocrit and immediately used for
experiments. hRBC mean volume in isotonic solution was determined using a CASY-1 Cell Counter
(Schärfe System GmbH, Reutlingen, Germany) and was calculated as 82 fL. Stopped-flow experiments
were performed on a HI-TECH Scientific PQ/SF-53 apparatus, with 2 ms dead time, temperature
controlled and were interfaced with a microcomputer. Measurements of water permeability (Pf) and
glycerol permeability (Pgly) were performed as described in References [12,33]. Briefly, 100 µL of
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the suspension of fresh erythrocytes (0.5%) was mixed with an equal volume of hyperosmotic PBS
containing 200 mM sucrose (a non-permeable osmolyte that induces water outflow and subsequent
cell shrinkage) and 200 mM glycerol (a permeable osmolyte that induces first fast cell shrinkage
due to water outflow and then glycerol influx in response to its chemical gradient, followed by
water influx with subsequent cell reswelling). The kinetics of cell volume change were measured
from the time course of 90◦ scattered light intensity at 400 nm until a stable light scatter signal was
attained. For each experimental condition, 5–7 replicates were analysed. Pf was estimated by Pf = k
(Vo/A)(1/Vw(osmout)∞), where Vw is the molar volume of water, Vo/A is the initial cell volume
to area ratio, (osmout)∞ is the final medium osmolarity after the applied osmotic gradient, and k
is the single exponential time constant fitted to the light scattering signal of erythrocyte shrinkage.
Pgly was estimated by Pgly = k (Vo/A), where k is the single exponential time constant fitted to the
light scattering signal of glycerol influx in erythrocytes.
In inhibition experiments, cells were incubated with different concentrations of complexes from
freshly prepared stock solutions, for 30 min at r.t. before stopped-flow experiments. A time-dependent
inhibition assay for all the tested compounds over several hours of incubation showed no further
increase of inhibition after 30 min at r.t. The inhibitor concentration necessary to achieve 50% inhibition
(IC50) was calculated by nonlinear regression of the dose-response curves (Graph Pad Prism, Inc,
San Diego, CA, USA) to the equation: y = ymin + (ymax − ymin)/(1 + 10((LogIC50 − Log[Inh])H)),
where y is the percentage inhibition obtained for each concentration of inhibitor [Inh], and H is the
Hill slope. All solution osmolarities were determined from freezing point depression on a semi-micro
osmometer (Knauer GmbH, Berlin, Germany) using standards of 100 and 400 mOsM.
3.7. Cell Lines and Culture Conditions
Human cell lines of lung adenocarcinoma (A549), breast carcinoma (MCF-7), ovarian
adenocarcinoma (SKOV-3) and skin malignant melanoma (A375) were obtained from American
Type Culture Collection (ATCC). The cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM, 4.5 g/L glucose, Corning, Thermo Fisher Scientific), supplemented with 10% foetal bovine
serum (One-Shot FBS, EU-approved South American Origin, Thermo Fisher Scientific) and 1%
penicillin/streptomycin (Gibco). All cell lines were cultured at 37 ◦C, in a humidified atmosphere of
5% CO2 and passaged when reaching confluence.
3.8. Immunocytofluorescence
Round glass coverslips (Ø 13mm, VWR) sterilized by UV-light exposure were inserted in
24-well tissue culture-treated plates (Corning) prior to the addition of cells. Cells were seeded at a
concentration of 125,000 cells/mL and incubated at 37 ◦C under humidified atmosphere with 5%
CO2, for 24 h. Glass coverslips were removed from the wells and washed three times with 1× PBS
(Gibco). Afterwards, cells were fixed for 20 min with 4% formaldehyde (Alfa Aesar) and permeabilized
for 5 min with 0.2% Triton X-100 (Alfa Aesar) at room temperature (r.t.). Glass coverslips were then
incubated with 1:500 primary anti-AQP3 antibody (rabbit anti-human, PA1488 BosterBio, Pleasanton,
CA, USA) in 1× PBS with 5% normal human serum (NHS, Invitrogen, UK), for 1 h at r.t., followed by
incubation with 1:500 secondary goat anti-rabbit Alexa Fluor®488 (ab150077, Abcam, Cambridge, MA,
US), in 1× PBS with 5% NHS for 1 h, at r.t. and in the dark. Before/after each step, cells were washed
thrice with 1× PBS. After removing excess PBS, cells were mounted on glass microscope slides (VWR)
using Mowiol® 4–88 (Sigma-Aldrich). Images were acquired on a Zeiss Axio Vert.A1 microscope and
processed using Fiji (ImageJ) [34].
3.9. Flow Cytometry Analysis
For flow cytometry evaluation of AQP3 expression, samples of each cell line studied were prepared
with 200,000 cells/sample. Cells were initially washed twice with 1× PBS (Gibco) and subsequently
fixed with 4% formaldehyde (Alfa Aesar) for 30 min at room temperature (r.t.). Afterwards, cells were
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incubated with 1:500 dilution of anti-AQP3 antibody (rabbit anti-human, PA1488 Boster), in 1× PBS
with 5% normal human serum (NHS, Invitrogen) and 0.1% Triton X-100 (Alfa Aesar) at r.t., for 1 h.
Staining with primary antibody was followed by incubation with 1:500 secondary goat anti-rabbit
Alexa Fluor®488 (ab150077, Abcam), in 1× PBS with 5% NHS and 0.1% Triton X-100 also for 1 h and at
r.t., in the dark. Cells were kept on ice and away from direct light until analysed using a BD FACS Verse
Flow Cytometer. Results were analysed using FlowJo 10.5.0. Firstly, samples were gated for live cells.
Afterwards, stained and unstained samples were compared, in order to gate the positive population
and the mean fluorescence, intensity (geometric mean) was taken from each positive sample peak.
Data were normalized for the sample with the lowest AQP3 expression and results are shown as mean
± SEM of three independent experiments.
3.10. Antiproliferative Activities
For evaluation of cell growth inhibition, cells were seeded in 96-well plates (Corning) at a
concentration of 15,000 cells/well, grown for 24 h in 200 µL complete medium. Solutions of the
samples with the desired concentration (1 to 100 µM) were prepared by diluting a freshly prepared stock
solution (10−2 M in DMSO) of the corresponding compound in aqueous DMEM medium, accordingly.
Auphen (stock solution 10 mM in DMSO) was used as the reference compound. A negative control
(medium only) was run for all the assays. After 24 h incubation, 200 µL of the compounds’ dilutions
were added to each well, and cells were incubated for an additional 72 h. Afterwards, medium was
removed and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Fluorochem) in
10× PBS (Corning) was added to the cells, at a final concentration of 0.3 mg/mL, and incubated
for 3–4 h. After, the MTT solution was discarded and replaced with DMSO, to allow the formed
violet formazan crystals to dissolve. The optical density was quantified in quadruplicates for each
experiment, at 550 nm using a multi-well plate reader (VICTOR X, Perking Elmer, UK). The percentage
of surviving cells was calculated from the ratio of absorbance of treated to untreated cells. The EC50
values were calculated, using GraphPad Prism software, as the concentration showed 50% decrease
in cell viability, compared to controls, using a nonlinear fit of concentration vs. response. Data is
presented as mean ±SEM of at least three independent experiments.
4. Conclusions
In conclusion, we have synthesized a new series of Au(III) compounds, cationic and neutral,
featuring a pyridine-benzimidazole scaffold, which has been characterized via different methods.
Varying the ligands’ substitution patterns influences the stability of the resulting Au(III) complexes in
aqueous environment, as demonstrated by UV–visible spectroscopy. In general, all the compounds
promptly react with the reducing agent GSH, except C11–C12. All the new gold-based complexes
are potent inhibitors of human water and glycerol channel aqualgyceoroporin-3 (AQP3), while they
are inactive as inhibitors of the water channel AQP1, as evidenced by stopped-flow spectroscopy in
hRBC. While most of the compounds are scarcely active as antiproliferative agents against human
cancer cells, the neutral complexes C10–C12 showed promising anticancer activities, particularly in
the melanoma A375 cancer cell line. Interestingly, while all the selected cell lines express AQP3,
the melanoma cells display protein expression also at the level of the nuclear membrane, as shown
by immunocytofluorescence. Thus, it may be hypothesized that C10–C12 targets mainly AQP3 in the
nuclear membrane after being taken up by the cancer cells. Overall, our results hold promise for the
design of novel selective AQPs inhibitors to be used anticancer agents or as chemical probes to study
the function of these interesting membrane channels.
Supplementary Materials: The following are available online at http://www.mdpi.com/2304-6740/6/4/123/s1,
CIF and checkCIF files. Scheme S1: Synthetic pathways to ligands L1–L12. Figure S1: 1H NMR (400.13 MHz,
CDCl3) spectrum of ligand L5. Figure S2: 13C{1H} NMR (100.61 MHz, CDCl3) spectrum of ligand L5. Figure S3:
1H NMR (400.14 MHz, CDCl3) spectrum of ligand L6. Figure S4: 13C{1H} NMR (100.61 MHz, CDCl3) spectrum
of ligand L6. Figure S5: 1H NMR (500.13 MHz, DMSO-d6) spectrum of complex C2. Figure S6: 13C{1H} NMR
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(125.77 MHz, DMSO-d6) spectrum of complex C2. Figure S7: 1H NMR (400.13 MHz, DMSO-d6) spectrum of
complex C3. Figure S8: 13C{1H} NMR (125.77 MHz, DMSO-d6) spectrum of complex C3. Figure S9: 1H NMR
(400.13 MHz, DMSO-d6) spectrum of complex C4. Figure S10: 13C{1H} NMR (125.77 MHz, DMSO-d6) spectrum of
complex C4. Figure S11: 1H NMR (400.13 MHz, DMSO-d6) spectrum of complex C5. Figure S12: 13C{1H} NMR
(100.61 MHz, DMSO-d6) spectrum of complex C5. Figure S13: 1H NMR (400.13 MHz, DMSO-d6) spectrum of
complex C6. Figure S14: 13C{1H} NMR (100.61 MHz, DMSO-d6) spectrum of complex C6. Figure S15: 1H NMR
(400.13 MHz, DMSO-d6) spectrum of complex C7. Figure S16: 13C{1H} NMR (100.61 MHz, DMSO-d6) spectrum
of complex C7. Figure S17: 1H NMR (400.13 MHz, DMSO-d6) spectrum of complex C8. Figure S18: 13C{1H}
NMR (100.61 MHz, DMSO-d6) spectrum of complex C8. Figure S19: 1H NMR (400.13 MHz, DMSO-d6) spectrum
of complex C9. Figure S20: 13C{1H} NMR (100.61 MHz, DMSO-d6) spectrum of complex C9. Figure S21: 1H
NMR (500.17 MHz, DMSO-d6) spectrum of complex C11. Figure S22: 13C{1H} NMR (125.77 MHz, DMSO-d6)
spectrum of complex C11. Figure S23: 1H NMR (500.17 MHz, MeCN-d3) spectrum of complex C12. Figure S24:
13C{1H} NMR (125.77 MHz, DMSO-d6) spectrum of complex C12. Figure S25: Absorption and emission spectra of
ligand L1. Figure S26: Absorption and emission spectra of complex C1. Figure S27: Absorption and emission
spectra of ligand L2. Figure S28: Absorption and emission spectra of complex C2. Figure S29: Absorption and
emission spectra of ligand L3. Figure S30: Absorption and emission spectra of complex C3. Figure S31: Absorption
and emission spectra of ligand L4. Figure S32: Absorption and emission spectra of complex C4. Figure S33:
Absorption and emission spectra of ligand L5. Figure S34: Absorption and emission spectra of complex C5.
Figure S35: Absorption and emission spectra of ligand L6. Figure S36: Absorption and emission spectra of
complex C6. Figure S37: Absorption and emission spectra of ligand L7. Figure S38: Absorption and emission
spectra of complex C7. Figure S39: Absorption and emission spectra of ligand L8. Figure S40: Absorption and
emission spectra of complex C8. Figure S41: Absorption and emission spectra of ligand L9. Figure S42: Absorption
and emission spectra of complex C9. Figure S43: Absorption and emission spectra of ligand L10. Figure S44:
Absorption and emission spectra of complex C10. Figure S45: Absorption and emission spectra of ligand L11.
Figure S46: Absorption and emission spectra of complex C11. Figure S47: Absorption and emission spectra of
ligand L12. Figure S48: Absorption and emission spectra of complex C12. Figure S49: UV–Visible spectra of
the Au(III) complex C1 (10−4 M) in PBS (pH 7.4) recorded over time (left); and of C1 before and after addition
of GSH (2 eq.) recorded over time at room temperature (right). Figure S50: UV–Visible spectra of the Au(III)
complex C2 (10−4 M) in PBS (pH 7.4) recorded over time (left); and of C2 before and after addition of GSH
(2 eq.) recorded over time at room temperature (right). Figure S51: UV–Visible spectra of the Au(III) complex C3
(10−4 M) in PBS (pH 7.4) recorded over time (left); and of C3 before and after addition of GSH (2 eq.) recorded
over time at room temperature (right). Figure S52: UV–Visible spectra of the Au(III) complex C4 (10−4 M) in PBS
(pH 7.4) recorded over time (left); and of C4 before and after addition of GSH (2 eq.) recorded over time at room
temperature (right). Figure S53: UV–Visible spectra of the Au(III) complex C5 (10−4 M) in PBS (pH 7.4) recorded
over time (left); and of C5 before and after addition of GSH (2 eq.) recorded over time at room temperature (right).
Figure S54: UV–Visible spectra of the Au(III) complex C6 (10−4 M) in PBS (pH 7.4) recorded over time (left);
and of C6 before and after addition of GSH (2 eq.) recorded over time at room temperature (right). Figure S55:
UV–Visible spectra of the Au(III) complex C7 (10−4 M) in PBS (pH 7.4) recorded over time (left); and of C7 before
and after addition of GSH (2 eq.) recorded over time at room temperature (right). Figure S56: UV–Visible spectra
of the Au(III) complex C8 (10−4 M) in PBS (pH 7.4) recorded over time (left); and of C8 before and after addition
of GSH (2 eq.) recorded over time at room temperature (right). Figure S57: UV–Visible spectra of the Au(III)
complex C9 (10−4 M) in PBS (pH 7.4) recorded over time (left); and of C9 before and after addition of GSH
(2 eq.) recorded over time at room temperature (right). Figure S58: UV–Visible spectra of the Au(III) complex C10
(10−4 M) in PBS (pH 7.4) recorded over time (left); and of C10 before and after addition of GSH (2 eq.) recorded
over time at room temperature (right). Figure S59: UV–Visible spectra of the Au(III) complex C11 (10−4 M) in PBS
(pH 7.4) recorded over time (left); and of C11 before and after addition of GSH (2 eq.) recorded over time at room
temperature (right). Figure S60: UV–Visible spectra of the Au(III) complex C12 (10−4 M) in PBS (pH 7.4) recorded
over time (left); and of C12 before and after addition of GSH (2 eq.) recorded over time at room temperature
(right). Figure S61: Normalized mean fluorescence intensity (MFI) of AQP3, detected using a secondary Alexa
Fluor®488-labelled antibody. Results were normalized for the sample with the lowest expression (A375) and
results are expressed as mean ±SEM of three independent experiments. * p < 0.03. Figure S62: X-ray structure of
crystals of C6. Thermal ellipsoids drawn at the 50% probability level. Figure S63: X-ray structure of crystals of
C7. Thermal ellipsoids drawn at the 50% probability level. Table S1: Antiproliferative activities (EC50 values) of
ligands in human SKOV-3, A375, MCF-7, and A549 cells after 72 h incubation.
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